Tetratherix Says Safety Review for Second Patient Group in Surgical Scar Prevention Product Trial Showed No Adverse Events; Shares Jump 5%
MT Newswires Live
Jan 13
Tetratherix (ASX:TTX) said the second safety review of the second patient group in the clinical trial of its TetraDerm product for the potential prevention of scar formation in surgical incisions was completed without any procedural or technical adverse events, according to a Tuesday Australian bourse filing.
Nine patients in the second group of the trial successfully completed their six-week follow up assessments, per the filing. Patient recruitment for the third group of the trial has started.
The company's shares jumped nearly 5% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.